The PSDV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PSDV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The PSDV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View PSDV Detailed Price Forecast - CNN Money||View PSDV Detailed Summary - Google Finance|
|View PSDV Detailed Summary - Yahoo! Finance||View PSDV Stock Research & Analysis - Zacks.com|
|View PSDV Trends & Analysis - Trade-Ideas||View PSDV Major Holders - Barrons|
|View PSDV Call Transcripts - NASDAQ||View PSDV Breaking News & Analysis - Seeking Alpha|
|View PSDV Annual Report - CompanySpotlight.com||View PSDV OTC Short Report - OTCShortReport.com|
|View PSDV Fundamentals - TradeKing||View PSDV SEC Filings - Bar Chart|
|View Historical Prices for PSDV - The WSJ||View Performance/Total Return for PSDV - Morningstar|
|View the Analyst Estimates for PSDV - MarketWatch||View the Earnings History for PSDV - CNBC|
|View the PSDV Earnings - StockMarketWatch||View PSDV Buy or Sell Recommendations - MacroAxis|
|View the PSDV Bullish Patterns - American Bulls||View PSDV Short Pain Metrics - ShortPainBot.com|
|View PSDV Stock Mentions - StockTwits||View PSDV Stock Mentions - PennyStockTweets|
|View PSDV Stock Mentions - Twitter||View PSDV Investment Forum News - Investor Hub|
|View PSDV Stock Mentions - Yahoo! Message Board||View PSDV Stock Mentions - Seeking Alpha|
|View Insider Transactions for PSDV - SECform4.com||View Insider Transactions for PSDV - Insider Cow|
|View PSDV Major Holdings Summary - CNBC||View Insider Disclosure for PSDV - OTC Markets|
|View Insider Transactions for PSDV - Yahoo! Finance||View Institutional Holdings for PSDV - NASDAQ|
|View PSDV Stock Insight & Charts - FinViz.com||View PSDV Investment Charts - StockCharts.com|
|View PSDV Stock Overview & Charts - BarChart||View PSDV User Generated Charts - Trading View|
EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Posted on Thursday April 19, 2018
EyePoint Pharmaceuticals, Inc. (EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter of fiscal year 2018 on Tuesday, May 8, 2018. Management will host a conference call to review the results at 4:30 p.m. ET on the same day. The conference ID is 1758647. A live webcast will be available on the Investor Relations section of the corporate website at http://www.eyepointpharma.com.
EyePoint Pharmaceuticals’ YUTIQ™ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Posted on Wednesday April 18, 2018
WATERTOWN, Mass., April 18, 2018-- EyePoint Pharmaceuticals, a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts ...
EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™
Posted on Thursday April 12, 2018
WATERTOWN, Mass., April 12, 2018-- EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that ...
pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners – Company Will Rebrand as EyePoint Pharmaceuticals, Inc.
Posted on Wednesday March 28, 2018
Acquisition and additional funding significantly accelerate the company’ s transformation to a specialty biopharmaceutical company with the potential to commercialize two ophthalmic products in 1 H 2019. ...